NEW YORK — Drugmakers Pfizer and Wyeth are closing in on a deal worth $68 billion that could be announced before the markets open Monday, according to published reports.

NEW YORK — Drugmakers Pfizer and Wyeth are closing in on a deal worth $68 billion that could be announced before the markets open Monday, according to published reports.

The New York Times and Wall Street Journal are reporting that Pfizer, the maker of Lipitor and Viagra, is working to finish financing for the acquisition Sunday evening.

A deal would increase Pfizer's revenue by half and add strength in biotech drugs, vaccines and consumer products.

Sources at Pfizer could not be immediately reached for comment. A Wyeth spokeman said the company had no comment.

At $68 billion, a deal between New York-based Pfizer Inc. and No. 12 drugmaker Wyeth of Madison, N.J., would be slightly larger than the $66 billion Sanofi-Aventis merger from August 2004.